U.S. RESEARCH ROUNDUP-Carnival, FedEx, Micron Technology June 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Carnival, FedEx and Micron Technology, on Thursday. HIGHLIGHTS * Carnival Corp CCL.N : Macquarie raises target price to $25 from $24 * FedEx Corp FDX.N : Daiwa Capital Markets raises target price to $318 from $296 * Micron Technology Inc MU.O : JP Morgan raises target price to $180 from $130 * Unifirst Cor

BRIEF-Exact Sciences Reaffirms Q2, FY Outlook June 3 (Reuters) - Exact Sciences Corp EXAS.O : EXACT SCIENCES: REAFFIRMS Q2 AND FY GUIDANCE, PROVIDED ON MAY 8 Source text for Eikon: [ID:n0001124140-24-000051] Further company coverage: EXAS.O

BUZZ-Exact Sciences down after US FDA advisers recommend Guardant's cancer test ** Shares of cancer diagnostics company Exact Sciences EXAS.O down 4.7% at $51.52 premarket ** Advisers to the U.S. FDA on Thursday recommended the approval of Guardant Health's GH.O blood test to detect a cancer that begins in the colon or rectum ** Tests for colorecta

CORRECTED-UPDATE 3-U.S. FDA advisers back approval for Guardant's blood-based cancer test (May 23) Corrects paragraph 4 of May 23 story to say Shield is meant for CRC screening, not diagnosis, and fixes typo in paragraph 7. The errors were also made in previous versions. By Puyaan Singh and Leroy Leo May 23 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's GH.O blood test to detect a cancer that begins in the colon or rect

U.S. FDA advisers back approval for Guardant's cancer test May 23 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's GH.O blood test to detect a cancer that begins in the colon or rectum. The panel voted seven-to-two in favor of benefits outweighing risks when using the test called Shield for colorectal cancer.

BUZZ-U.S. STOCKS ON THE MOVE-Hilton Grand Vacations, natgas firms, Silvaco Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The main U.S. stock indexes rose on Thursday as weekly jobless claims data offered fresh evidence of a softening U.S.

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Energy Transfer, Aercap Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The main U.S. stock indexes rose on Thursday as weekly jobless claims data offered fresh evidence of a softening U.S. labor market and renewed hopes that the Federal Reserve will cut interest rates this year.

BUZZ-U.S. STOCKS ON THE MOVE-Plug Power, Cheesecake Factory, HubSpot Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures slipped on Thursday as Treasury yields extended gains ahead of jobless claims data that is expected to offer more clues on the Federal Reserve's monetary policy path for the year.

BUZZ-U.S. STOCKS ON THE MOVE-Exact Sciences, Sezzle, Robinhood Markets Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures slipped on Thursday as Treasury yields rose further ahead of jobless claims data that could provide a clearer picture of the Federal Reserve's interest rate agenda for the year.

BUZZ-Exact Sciences falls on wider Q1 loss ** Shares of cancer test maker Exact Sciences EXAS.O fall 16.9% to $49.45 premarket ** Company, after market on Wednesday, posted a Q1 loss of 60 cents/shr vs 42 cents/shr a year ago ** But Q1 revenue of $637.5 mln up 5.8% from the year earlier ** EXAS reaffirms 2024 revenue forecast at $2.81 bln to $2.85

BRIEF-Exact Sciences Q1 Basic EPS USD -0.6 May 08 (Reuters) - Exact Sciences Q1 pretax profit USD -108.422 million vs. IBES estimate USD -81.3 million. Q1 income from operations USD -106.692 million Q1 net income USD -110.228 million vs. IBES estimate USD -84.7 million Q1 revenue USD 637.524 million vs. IBES estimate USD 627.4 million outlook FY re

Exact Sciences Corp expected to post a loss of 47 cents a share - Earnings Preview Exact Sciences Corp EXAS.OQ EXAS.O is expected to show a rise in quarterly revenue when it reports results on May 8 for the period ending March 31 2024 The Madison Wisconsin-based company is expected to report a 4.1% increase in revenue to $627.365 million from $602.45 million a year ago, according to the mean estimate from 20 analysts, based on LSEG data.The company's guidance on February 21 2024, for the perio